Standardizing Haemophilia Care in India: A Vital Shift

Haemophilia care in India requires a transformative approach to improve patient outcomes and streamline management across various states. Experts highlight that nearly 80 percent of cases remain undetected because of low awareness and screening gaps. Consequently, the adoption of national standard treatment guidelines (STGs) is now a top priority for health advocates. These guidelines aim to provide a uniform framework for diagnosis and long-term management while accounting for local resource constraints.

The Need for Standardized Haemophilia Care in India

Early diagnosis remains a significant hurdle because haemophilia is frequently misdiagnosed as arthritis in children. This error leads to avoidable joint damage and the eventual need for complex replacement surgeries. However, standard treatment guidelines could help clinicians identify the disorder much sooner. Furthermore, many mild cases only surface during surgical procedures or routine dental extractions. Therefore, doctors must emphasize family history and report prolonged bleeding promptly to avoid complications. Additionally, India-specific guidelines would ensure equitable access to care across diverse geographic and social contexts. Moreover, a uniform framework would reduce the current reliance on reactive treatment strategies that only address emergencies.

Advancing from Reactive to Preventive Therapy

Treatment in India has traditionally been reactive, where patients seek help only after a painful bleeding episode occurs. In contrast, high-income countries utilize prophylaxis for 80-90 percent of their patients to prevent joint damage. Only about 4 percent of Indian patients currently receive such preventive care. Newer non-factor therapies, which are administered subcutaneously, offer a promising solution for the local population. These therapies significantly reduce bleeding frequency and are much easier to administer than traditional methods. Some state governments have already started providing these advanced treatments to those in need. Consequently, the transition to prophylaxis as the standard of care is essential to prevent long-term disability. Uniform guidelines will support this shift by providing clear protocols for clinicians nationwide.

Frequently Asked Questions

Q1: Why is haemophilia often underdiagnosed in India?

Haemophilia is often underdiagnosed because of a lack of public awareness and symptoms that mimic other conditions like juvenile arthritis. Many mild cases remain undetected until an individual undergoes surgery or experiences a significant injury.

Q2: What is the benefit of prophylaxis over on-demand treatment?

Prophylaxis involves regular treatment to prevent bleeding before it starts. This approach significantly reduces long-term joint damage and improves the overall quality of life compared to treating episodes after they occur.

Q3: How do non-factor therapies help in haemophilia management?

Non-factor therapies are easier to administer than traditional clotting factors because they are given subcutaneously. They provide more stable protection and significantly lower the frequency of spontaneous bleeding episodes.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Experts urge standard treatment guidelines to streamline haemophilia care inIndia - ETHealthworld


2. World Federation of Hemophilia. WFH Guidelines for the Management of Hemophilia, 3rd edition.


3. National Health Mission, Ministry of Health and Family Welfare, Government of India. Guidelines on Hemoglobinopathies and Hemophilia.